Advances in surgical techniques have reduced the need for blood transfusion and most anaemias can now be managed without transfusions. While the haemoglobin concentration assists the decision to transfuse a patient, there is no single threshold for transfusion. The need to give a blood component is also difficult to assess, but guidelines are available. Although Australian blood supplies have a high degree of safety, attention to details such as patient identification and compatibility will help to reduce adverse outcomes when a transfusion is indicated.
Introduction
The transfusion of blood or its components (plasma, platelets, cryoprecipitate) has an important role in modern medicine and surgery. However, in recent years this role has been reassessed, especially in anaemia and in the perioperative setting.
The majority of anaemias can now be treated without the transfusion of homologous blood, and careful risk assessment and the use of blood conservation techniques have made 'bloodless' surgery possible for most elective procedures.
Indications for blood transfusion
Blood transfusion is indicated to control the effects of a haematological deficiency, or to prevent problems, until the injury or disease process can be corrected or resolves. The focus should be on the patient's specific clinical problem, with transfusion viewed as an option only when alternatives have been considered and optimally used when possible.
Assessing acute blood loss and when to start transfusion remains controversial. However, it is reasonable to say that volume resuscitation does not need blood in the first instance.
The decision to use blood should be made in the context of the patient's cardiocirculatory and respiratory status and haemoglobin level after resuscitation with clear fluid. If blood loss is accurately assessed a better prediction as to when red cell transfusion may be needed can be made. Use of red blood cells may be appropriate when Hb is 70-100 g/L. In such cases, the decision to transfuse should be supported by the need to relieve clinical signs and symptoms and prevent significant morbidity and mortality.
Use of red blood cells is likely to be appropriate when Hb<70 g/L. In some patients who are asymptomatic and/or where specific therapy is available, lower threshold levels may be acceptable.
In the context of acute bleeding and hypovolaemia, the haemoglobin is only one consideration in determining the need for red blood cells. Additional factors to consider include the patient's cardiopulmonary reserve, total volume of blood loss, oxygen consumption and arterial disease.
Platelet concentrates Prophylaxis
Bone marrow failure when the platelet count is <10 x 10 9 /L without risk factors or <20 x 10 9 /L in the presence of additional risk factors (e.g. fever,
antibiotics, evidence of systemic haemostatic failure).
Maintaining the platelet count at >50 x 10 9 /L in patients undergoing surgery or invasive procedures.
Inherited or acquired qualitative platelet function disorders, depending on clinical features and setting. In these situations the platelet count is not a reliable indicator for transfusion.
Haemorrhage Use of platelets is likely to be appropriate in any patient who is bleeding when thrombocytopenia is considered a major contributory factor and when the platelet count is <50 x 10 9 /L in the context of massive haemorrhage/transfusion and <100 x 10 9 /L in the presence of diffuse microvascular bleeding.
Fresh frozen plasma Replacement of single factor deficiencies where a specific or combined factor concentrate is not available.
Immediate reversal of warfarin effect in the presence of potentially life-threatening bleeding when used in addition to vitamin K and possibly prothrombin complex concentrate (prothrombinex-HT).
Treatment of the multiple coagulation deficiencies associated with acute disseminated intravascular coagulation.
Treatment of inherited deficiencies of coagulation inhibitors in patients undergoing high-risk
procedures where a specific factor concentrate is unavailable.
In the presence of bleeding and abnormal coagulation parameters following massive transfusion or cardiac bypass surgery or in patients with liver disease. Tables 1 and 2 ). If there is a reasonable probability of a patient requiring a red cell transfusion a sample of blood should be sent to the laboratory for 'type and screen'. Units of blood will only be released upon specific request by the clinician.
The clinician's responsibilities
The clinician requires a core knowledge of transfusion medicine focusing on the following: 7. Who will administer and monitor the blood component?
8. What end points will be measured to assess benefit? 9. Is the patient appropriately informed about the risks and benefits of transfusion or no transfusion?
10. Is the transfusion process being correctly documented and audited, from the decision to transfuse through to end points and complications?
